Literature DB >> 16650739

Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.

Anne H de Boer1, Paul Hagedoorn, Elsbeth M Westerman, Paul P H Le Brun, Harry G M Heijerman, Henderik W Frijlink.   

Abstract

Dry powder inhalation of antibiotics in cystic fibrosis (CF) therapy may be a valuable alternative for wet nebulisation, because it saves time and it improves lung deposition. In this study, it is shown that the use of multiple air classifier technology enables effective dispersion of large amounts of micronised powder (up to 25mg). X(50)-values of the aerosol from laser diffraction analysis obtained with the Twincer disposable inhaler concept (containing multiple air classifier technology) are practically the same as that for the pure drug in the range of dose weights between 0 and 25mg. Only for the highest dose weights, a minor fraction (5-7.5%) of small agglomerates (5-15microm) is released from the inhaler. Moreover, the size distribution of the aerosol is practically the same at 1 and 4kPa. Cascade impactor results confirm the good performance of the multiple classifier concept. Unprocessed micronised particles or soft spherical agglomerates can be used, and special particle engineering processes are not necessary. Only a minor fraction of coarse sweeper crystals in the formulation is desired to reduce the total inhaler losses for colistin sulfomethate to less than 5-6% at 4kPa. The classifiers can be designed to retain these crystals with more than 95% efficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650739     DOI: 10.1016/j.ejps.2005.11.013

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  11 in total

1.  Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.

Authors:  Qi Tony Zhou; Thomas Gengenbach; John A Denman; Heidi H Yu; Jian Li; Hak Kim Chan
Journal:  AAPS J       Date:  2013-10-16       Impact factor: 4.009

Review 2.  Devices for dry powder drug delivery to the lung.

Authors:  Kai Berkenfeld; Alf Lamprecht; Jason T McConville
Journal:  AAPS PharmSciTech       Date:  2015-05-12       Impact factor: 3.246

3.  Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Yang Hu; Nikolas J Onufrak; Siping Sun; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

5.  Tissue heme oxygenase-1 exerts anti-inflammatory effects on LPS-induced pulmonary inflammation.

Authors:  F M Konrad; U Knausberg; R Höne; K-C Ngamsri; J Reutershan
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

Review 6.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

Review 7.  Developments in the formulation and delivery of spray dried vaccines.

Authors:  Gaurav Kanojia; Rimko Ten Have; Peter C Soema; Henderik Frijlink; Jean-Pierre Amorij; Gideon Kersten
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

8.  Targeting the small airways with dry powder adenosine: a challenging concept.

Authors:  Erica van der Wiel; Anne J Lexmond; Maarten van den Berge; Dirkje S Postma; Paul Hagedoorn; Henderik W Frijlink; Martijn P Farenhorst; Anne H de Boer; Nick H T Ten Hacken
Journal:  Eur Clin Respir J       Date:  2017-09-06

9.  Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus.

Authors:  Yoshita Bhide; Jasmine Tomar; Wei Dong; Jacqueline de Vries-Idema; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

10.  Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine.

Authors:  Imco Sibum; Paul Hagedoorn; Markus P G Kluitman; Martijn Kloezen; Henderik W Frijlink; Floris Grasmeijer
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.